Suboxone® (Buprenorphine/Naloxone) as an Agonist Opioid Treatment in Spain: A Budgetary Impact Analysis

Publisher： Karger

E-ISSN： 1421-9891|16|1|31-42

ISSN： 1022-6877

Source： European Addiction Research, Vol.16, Iss.1, 2009-11, pp. : 31-42

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The introduction of buprenorphine‐naloxone film in opioid substitution therapy in Australia: Uptake and issues arising from changing buprenorphine formulations

By  

DRUG AND ALCOHOL REVIEW, Vol. 34, Iss. 6, 2015-11 ,pp. : 603-610

John Wiley & Sons Inc

Access to resources Recommend Favorite

Injecting buprenorphine‐naloxone film: Findings from an explorative qualitative study

By  

DRUG AND ALCOHOL REVIEW, Vol. 34, Iss. 6, 2015-11 ,pp. : 623-629

John Wiley & Sons Inc

Access to resources Recommend Favorite

Comparison of Buprenorphine and Methadone in the Treatment of Opioid Dependence

By  

European Addiction Research, Vol. 4, Iss. 1, 1998-10 ,pp. : 13-18

Karger

Access to resources Recommend Favorite

International patent applications for non‐injectable naloxone for opioid overdose reversal: Exploratory search and retrieve analysis of the PatentScope database

By  

DRUG AND ALCOHOL REVIEW, Vol. 37, Iss. 2, 2018-02 ,pp. : 205-215

John Wiley & Sons Inc

Access to resources Recommend Favorite

Budgetary Impact Analysis of Reimbursement Varenicline for the Smoking-Cessation Treatment in Patients with Cardiovascular Diseases, Chronic Obstructive Pulmonary Disease or Type-2 Diabetes Mellitus: A National Health System Perspective

By  

European Addiction Research, Vol. 23, Iss. 1, 2016-10 ,pp. : 7-18

Karger

Access to resources Recommend Favorite